There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Coherus Biosciences (CHRS – Research Report) and BerGenBio AS (BRRGF – Research Report) with bullish sentiments.
Coherus Biosciences (CHRS)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Coherus Biosciences, with a price target of $24.00. The company’s shares closed last Monday at $4.98, close to its 52-week low of $3.60.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 14.6% and a 46.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Crinetics Pharmaceuticals.
Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $15.56, representing a 242.0% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $8.00 price target.
BerGenBio AS (BRRGF)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on BerGenBio AS today and set a price target of NOK30.00. The company’s shares closed last Tuesday at $0.20.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of 4.2% and a 43.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for BerGenBio AS with a $1.38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CHRS: